介入化疗联合口服替吉奥胶囊治疗进展期胃癌的疗效和安全性分析

The efficacy and safety of chemotherapy combined with oral tegafur capsules in treatment of advanced gastric cancer

目的探讨介入化疗联合口服替吉奥胶囊治疗进展期胃癌的疗效和安全性。方法将60例经病理证实为进展期胃癌的患者随机分为对照组与观察组各30例。对照组采取单纯动脉介入化疗,化疗方案为:0.5 g/m25-Fu+50 mg表柔比星+130 mg/m2奥沙利铂;观察组在此基础上口服替吉奥胶囊治疗,50 mg,2次/d,比较两组临床疗效、治疗前后免疫功能及不良反应发生率。结果 (1)对照组临床总有效率为63.33%,显著低于观察组(83.33%)(P<0.05);(2)两组治疗前后免疫功能指标(IgG、IgM及IgA)相比,差异均具有统计学意义(P<0.05,P<0.01),且两组治疗后免疫功能相比,差异均具有统计学意义(P<0.05)。结论介入化疗联合口服替吉奥胶囊治疗进展期胃癌的疗效较好,应在临床上加以推广并应用。

Objective To explore the efficacy and safety of interventional chemotherapy combined with oral tegafur cap- sules in treatment of advanced gastric cancer. Methods Sixty patients were randomly divided into control group and observation group of 30 cases. Control group taken simple arterial infusion chemotherapy regimens as ： 0.5 g/m2 of 5-Fu ＋50 mg epirubiein ＋130 mg/m2 oxaliplatin; observation group on the basis of the treatment was given Gio capsules,50 mg,2 times / d.Clinical efficacy were compared before and after treatment immune function and incidence of adverse reactions. Results （1）The total effective rate of control group was 63.33% ,was significantly lower than the observation group （83.33%）（P〈0.05）.（2） Immune function before and after treatment （IgG,IgM and IgA）changed,the differences were statistically significant （P〈0.05, P〈0.01 ）, and immune function after treatment compared with the before threatment, the differences were statistically significant （P 〈0.05）. Conclusion The efficacy of chemotherapy combined with oral tegafur capsules in the treatment of advanced gastric cancer is good, should be promoted and applied clinically.